News headlines about Avenue Therapeutics (NASDAQ:ATXI) have trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Avenue Therapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news articles about the company an impact score of 42.8366126426646 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Avenue Therapeutics (NASDAQ ATXI) traded down $0.28 during trading hours on Tuesday, hitting $4.35. 23,700 shares of the stock traded hands, compared to its average volume of 29,844. Avenue Therapeutics has a one year low of $3.91 and a one year high of $8.58.
Avenue Therapeutics (NASDAQ:ATXI) last released its earnings results on Thursday, November 9th. The company reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.05).
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/11/14/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-avenue-therapeutics-atxi-share-price.html.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain.
Receive News & Ratings for Avenue Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.